干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊

干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊干細(xì)胞概述干細(xì)胞培養(yǎng)細(xì)胞因子產(chǎn)品目錄010308020610間充質(zhì)干細(xì)胞（MSC）胚胎和誘導(dǎo)多能干細(xì)胞（ESC/iPSC）造血干細(xì)胞（HSC）神經(jīng)干細(xì)胞（NSC）不同細(xì)胞因子對MSC的作用應(yīng)用案例MSC細(xì)胞因子推薦

MSC鑒定試劑盒ESC/iPSC細(xì)胞因子推薦產(chǎn)品驗證數(shù)據(jù)HSC細(xì)胞因子推薦產(chǎn)品驗證數(shù)據(jù)NSC細(xì)胞因子推薦產(chǎn)品驗證數(shù)據(jù)北京義翹神州科技股份有限公司01干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊全能干細(xì)胞卵裂球胚胎干細(xì)胞間充質(zhì)干細(xì)胞骨生成軟骨生成肌生成肌肉軟骨骨分化和成熟其它例：骨髓、脂肪和皮膚髓質(zhì)淋巴細(xì)胞紅細(xì)胞白細(xì)胞血小板B細(xì)胞T細(xì)胞神經(jīng)元星形膠質(zhì)細(xì)胞少突膠質(zhì)細(xì)胞NK細(xì)胞造血干細(xì)胞神經(jīng)干細(xì)胞誘導(dǎo)多能干細(xì)胞多能干細(xì)胞專能干細(xì)胞體細(xì)胞重編程因子(c-Myc、Klf4、Oct4和Sox2）單能干細(xì)胞簡介干細(xì)胞是一類具有自我更新、自我復(fù)制和分化成多種細(xì)胞系能力的多潛能細(xì)胞，包括間充質(zhì)干細(xì)胞、造血干細(xì)胞、神經(jīng)干細(xì)胞、胚胎和誘導(dǎo)多能干細(xì)胞等。近年來，各種類型的干細(xì)胞在疾病治療方面已取得了重大進(jìn)展，尤其在治療癌癥、心臟病、糖尿病、克羅恩病等疾病方面具有潛在的應(yīng)用價值。細(xì)胞因子在干細(xì)胞研究中發(fā)揮著不可或缺的作用，表現(xiàn)在：細(xì)胞因子可以控制干細(xì)胞的增殖和分化。如：Activin

A能夠促進(jìn)誘導(dǎo)多能干細(xì)胞向內(nèi)胚層分化。細(xì)胞因子對干細(xì)胞的遷移定位，具有靶向調(diào)控作用。如：損傷或炎癥處的免疫細(xì)胞所分泌的TNF-α和BMP-4等細(xì)胞因子，可以促進(jìn)間充質(zhì)干細(xì)胞對損傷處的定位與遷移，從而促進(jìn)損傷的組織細(xì)胞的修復(fù)。更多其他作用。EGF被證明能夠提高來自胚胎大腦的神經(jīng)干細(xì)胞的存活率，LIF能夠調(diào)節(jié)干細(xì)胞多能性，F(xiàn)GF2也已被確定為多種干細(xì)胞類型的關(guān)鍵調(diào)節(jié)因子。干細(xì)胞分化圖譜干細(xì)胞概述北京義翹神州科技股份有限公司02干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊DEPARTMENT

OF

HEALTH

AND

HUMAN

SERVICESFood

and

Drug

Administration

Silver

Spring,

MD

20993DMF035978DMF

ACKNOWLEDGEMENTSINO

BIOLOGICAL,

INC.Attention:

ZHIQIANG

ZHANBUILDING

9,

JING

DONGHEI

TECHNOLOGY

PARKNO.

18

KECHUANG

10TH

ST,

BDA,

BEIJING,

100176,

CHINADear

ZhiqiangZhan,TheFoodandDrugAdministrationacknowledgesreceiptofthefollowingDrugMaster

File(DMF)submission:DMF

NUMBER

ASSIGNED:

035978DATEOF

SUBMISSION:

MAY

27,

2021DMF

TYPE:

IISUBJECT

(TITLE):

SUPERNUCLEASEHOLDER:

SINO

BIOLOGICAL,

INC.SUBMITTED

BY:

SINO

BIOLOGICAL,

INC.AGENT:

NONEAllsubsequent

correspondenceto

this

DMFshould

beidentified

with

theinformation

as

providedabove.YourDMFwillbereviewedonlyinconnectiontoaNew

DrugApplication,AbbreviatedNew

Drug

Application,

Investigational

New

Drug

Application,

Biological

License

Application,

New

Animal

Drug

Application,

Abbreviated

New

Animal

Drug

Application,

Investigational

New

Animal

Drug

Application,

or

DMFit

isintended

tosupport

whena

Letterof

Authorization(LOA)

issubmitted

tothe

DMFand

acopy

ofthe

LOA

is

submitted

in

the

application

e.g.,

NDA,

that

references

the

DMF.Forinformation

on

variousDMF

submissions,

example

ofletter

templates

and

DMFGuidance

for

Industry,

check

the

DMF

website

at

/drugs/forms-submission-requirements/drug-master-files-dmfsThe

holder

of

the

DMF

is

responsible

for

compliance

with

21

CFR314.420

as

interpreted

in

“The

Guideline

for

Drug

Master

Files”

at

/drugs/drug-master-files-dmfs/guideline-drug-master-files-dmfYou

are

expected

to:Adhereto

thestatement

ofcommitment

you

haveprovided.

Providethe

followingsubmissions

tothe

DMF:Letters

of

Authorization

(LOAs)

granting

permission

to

a

third

party

(authorized

party)

or

self

toreferencetheDMFandforFDAtoreviewthe

DMF.

Listinganauthorizedpartyinthe

AnnualReport

isnot

sufficientto

authorizethat

party

toreference

theDMF.

Submissionof

a

copyof

theLOA

tothe

authorized

partywithout

submittingthe

originalLOA

to

theDMF

(with

DMFnumber)

is

also

not

sufficient

to

authorize

thatparty

to

reference

the

DMF.Anychange,additionordeletionofinformationAnnual

Reports

tothe

DMFcontaining:Reference

ID:

4802568ISO

9001:2015認(rèn)證2024年值得關(guān)注的生長因子供應(yīng)商ISO

13485:2016認(rèn)證GMP認(rèn)證ISO

17025:2017證書FDA

DMF備案作為全球重組技術(shù)的領(lǐng)導(dǎo)者，義翹神州開發(fā)了一系列高品質(zhì)干細(xì)胞培養(yǎng)重組細(xì)胞因子，包括EGF、PDGF-BB、TGF

beta

1、SCF、IGF1和

basic

FGF/FGF2等，具有高純度、高生物活性、低內(nèi)毒素和高批間一致性等特點，涵蓋研究級和GMP級。此外，我們還提供干細(xì)胞標(biāo)志物抗體和鑒定試劑盒等產(chǎn)品，全面支持多種類型干細(xì)胞的研究。高純度：純度>95%（SDS-PAGE、HPLC檢測）高生物活性：經(jīng)ELISA、cell-based

assays驗證

低內(nèi)毒素：

5-10

EU/mg高批間一致性種類齊全：涵蓋研究級和GMP級細(xì)胞因子質(zhì)量控制：通過ISO

9001/ISO

13485/GMP等多重質(zhì)量體系認(rèn)證產(chǎn)品優(yōu)勢資質(zhì)證書干細(xì)胞培養(yǎng)細(xì)胞因子產(chǎn)品03干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊細(xì)胞因子功能產(chǎn)品推薦basic

FGF/FGF2提高M(jìn)SC的增殖支持軟骨細(xì)胞的增殖和分化GMP-10014-HNAEEGF刺激MSC的增殖，但不改變MSC分化潛能增強MSC的旁分泌和自分泌功能GMP-10605-HNAEPDGF-BB促進(jìn)MSC的增殖與存活促進(jìn)肌細(xì)胞增殖10572-HNAETGFbeta

1促進(jìn)MSC的增殖促進(jìn)MSC向軟骨細(xì)胞分化10804-HNACIGF-1促進(jìn)MSC的增殖誘導(dǎo)MSC向軟骨細(xì)胞分化10598-HNAESCF促進(jìn)MSC的增殖10451-HNAEVEGF-A促進(jìn)MSC的增殖與存活參與血管內(nèi)皮細(xì)胞的形成、增殖與存活10008-HNAH間充質(zhì)干細(xì)胞（Mesenchymal

stem

cells,

MSC）是一類存在于多種組織（如臍帶、骨髓和脂肪組織等），具有自我更新和分化能力的成體干細(xì)胞。研究表明，間充質(zhì)干細(xì)胞通過調(diào)節(jié)與先天性和適應(yīng)性免疫系統(tǒng)相關(guān)的淋巴細(xì)胞從而發(fā)揮免疫調(diào)節(jié)和抗炎作用。因此，MSC在自身免疫性疾病、心血管疾病、炎癥性疾病、神經(jīng)退行性疾病等多種疾病治療中具有重要作用。間充質(zhì)干細(xì)胞因其獲取便捷、遺傳穩(wěn)定性高、免疫原性低以及具有組織修復(fù)和免疫調(diào)節(jié)功能的治療特性，在疾病治療領(lǐng)域具有廣闊的應(yīng)用前景。不同細(xì)胞因子對MSC的作用間充質(zhì)干細(xì)胞培養(yǎng)血管生成骨生成軟骨生成脂肪生成肌肉生成內(nèi)皮細(xì)胞成骨細(xì)胞 軟骨細(xì)胞 脂肪細(xì)胞參與間充質(zhì)干細(xì)胞分化的細(xì)胞因子示意圖肌細(xì)胞MSCTGF-β

FGF-2

PDGF

EGF祖細(xì)胞池BMP2

BMP4

BMP5

FGF2

IGF-1TGF-βWntsBMP2

BMP4

FGF2

IGF-1TGF-βVEGFBMP2

BMP4BMP4

FGF2PDGF-BBGMP級細(xì)胞因子，現(xiàn)貨供應(yīng)北京義翹神州科技股份有限公司北京義翹神州科技股份有限公司04干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊細(xì)胞因子貨號種屬表達(dá)宿主純度內(nèi)毒素basicFGF/FGF210014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgGMP-10014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgEGF10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgGMP-10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgPDGF-BB10572-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

50

EU/mgTGFbeta

110804-HNACHuman,

Rhesus,Cynomolgus,

CanineCHO

Stable

Cells95%

SDS-PAGE<

1

EU/μg10804-H08HHumanHEK293Cells95%

SDS-PAGE<

1

EU/μgSCF10451-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgGMP-10451-HNAE1-L-AFHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgVEGF-A10008-HNAHHumanHEK293Cells95%

SDS95%

SEC-HPLC<

1

EU/μgBMP-210426-HNAE1Human,

Mouse,

Rat,Rhesus,

CanineE.

coli≥

95%

SDS<

10

EU/mgBMP410609-HNAE2HumanE.

coli≥

95%

SDS<

1

EU/μgTransdifferentiationEGF

(20

ng/mL)bFGF(10

ng/mL)HepaticinductionHGF

(20

ng/mL)bFGF(10

ng/mL)NTA

(0.61

g/L)MaturationOSM

(20

ng/mL)Dexa

(1

umol/L)ITX

(1

X)2

days1week(a)1weekD1D7D14IAR2025

m間充質(zhì)干細(xì)胞分化為肝樣細(xì)胞更多MSC培養(yǎng)細(xì)胞因子推薦骨髓間充質(zhì)干細(xì)胞的增殖MSC培養(yǎng)細(xì)胞因子應(yīng)用案例GMP級細(xì)胞因子，現(xiàn)貨供應(yīng)用到的產(chǎn)品：

EGF、bFGF、HGF（a）體外誘導(dǎo)間充質(zhì)干細(xì)胞分化為肝樣細(xì)胞流程圖（b）間充質(zhì)干細(xì)胞向肝樣細(xì)胞分化的形態(tài)圖。DOI:

10.1155/2023/6890299P0為原代細(xì)胞，P1、P2、P3分別代表第1、2、3代細(xì)胞。

DOI:

10.1186/s12974-022-02393-2用到的產(chǎn)品：EGF（Cat#:

50482-MNCH）、FGF-18（Cat#:

50177-M08H）無動物源細(xì)胞因子北京義翹神州科技股份有限公司05干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊NormalizedToModeNormalizedToModeNormalizedToMode100

100

10080

80

8060

60

6040

40

4020

20

200

0

0100

101

102

103

104

100

101

102

103

104

100

101

102

103

104FITC

NegativeCocktail

PE

CD73

PerCP

CD90NormalizedToMode100

101NormalizedToMode102

103

104

100

101APC

CD105102

103

104FITC

CD44NormalizedToMode0

0

0100

101102APC

CD166103

104CD

E100

100

10080

80

8060

60

6040

40

4020

20

20F人間充質(zhì)干細(xì)胞鑒定試劑盒（Cat#:

HMSC07）分析間充質(zhì)干細(xì)胞流式結(jié)果圖A

B目前，MSC的鑒定方法主要有三種：形態(tài)學(xué)觀察細(xì)胞是否呈貼壁狀態(tài)、多向分化潛能鑒定和MSC表面標(biāo)志物鑒定。2006年，國際細(xì)胞治療學(xué)會（ISCT）提出了一種細(xì)胞表面標(biāo)記物組合，用于鑒定人類間充質(zhì)干細(xì)胞。根據(jù)該建議，MSC的細(xì)胞表面標(biāo)志物CD73、CD90和CD105應(yīng)呈陽性，而CD34、CD45、CD11b或CD14、CD19或CD79α和HLA-DR呈陰性。Cultured

hMSCs

from

umbilical

cord

are

analyzed

by

HMSC07.

Cells

demonstrate

negative

expression

of

CD45,

CD34,

CD14,

CD19,HLA-DR(?gure

A)

as

well

as

positive

expression

of

CD73

(Figure

B),

CD90

(Figure

C),

CD105

(Figure

D),

CD44

(Figure

E),

CD166(Figure

F).

The

blue

linesarecells

withisotypeantibodies.

The

redlines

arecellswith

antibodiestargetingto

marker.人間充質(zhì)干細(xì)胞鑒定試劑盒推薦義翹神州提供兩款人MSC鑒定試劑盒Cat#:

HMSC03

Cat#:

HMSC07其中HMSC03

試劑盒覆蓋所有8個抗體的檢測，HMSC07試劑盒又在此基礎(chǔ)上添加了CD44和CD166的檢測，表面標(biāo)志物覆蓋全面。北京義翹神州科技股份有限公司06干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊參與胚胎和誘導(dǎo)多能干細(xì)胞分化的細(xì)胞因子示意圖胚胎和誘導(dǎo)多能干細(xì)胞培養(yǎng)內(nèi)胚層VEGFEGFFGF2FGF4BMP4TGFbetaHGHVEGFFGF2BMP4VEGFFGF2EGFSCFEGFBMP4FGF2EGFBMP4FGF2VEGFFGF2TGFbetaSCFIL-3IL-6IL-11VEGFBMP4定型內(nèi)胚層內(nèi)皮細(xì)胞角質(zhì)細(xì)胞表皮細(xì)胞神經(jīng)祖細(xì)胞星形膠質(zhì)細(xì)胞皮層神經(jīng)元神經(jīng)嵴干細(xì)胞少突細(xì)胞間充質(zhì)干細(xì)胞/前體細(xì)胞骨骼成肌細(xì)胞平滑肌細(xì)胞造血祖細(xì)胞紅細(xì)胞生成細(xì)胞淋巴樣祖細(xì)胞單核細(xì)胞/巨噬細(xì)胞祖細(xì)胞后腸內(nèi)胚層腸組織肝細(xì)胞多能性肺祖細(xì)胞中胚層多能干細(xì)胞（ESC/iPSC）外胚層生殖細(xì)胞類外胚層細(xì)胞精子類卵母細(xì)胞+類卵泡結(jié)構(gòu)胚胎干細(xì)胞（Embryonic

stem

cell,ESC）和誘導(dǎo)性多能干細(xì)胞（Induced

pluripotent

stem

cells,iPSC）均屬于多能干細(xì)胞，具有無限的自我更新能力，能夠分化成任何類型的細(xì)胞。ESC是目前最廣為人知的多能干細(xì)胞，但由于其來源于人類胚胎，潛在的倫理問題成為限制其廣泛使用的一大因素。iPSC是從成熟的體細(xì)胞轉(zhuǎn)化而來，其特性與胚胎干細(xì)胞十分相似，具備無限的自我更新和分化能力，在再生醫(yī)學(xué)、疾病建模、藥物測試和創(chuàng)新的細(xì)胞/基因療法方面擁有巨大的潛力。GM-CSF、ActivinA、DLL4、NOG、TNF-α、IL-2、VEGF、FGF、IL1β和EGF等細(xì)胞因子在調(diào)控人類iPSCs分化為各種細(xì)胞系的生理過程中發(fā)揮著重要作用。北京義翹神州科技股份有限公司07干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊ESC/iPSC培養(yǎng)細(xì)胞因子推薦產(chǎn)品驗證數(shù)據(jù)展示GMP級細(xì)胞因子，現(xiàn)貨供應(yīng)細(xì)胞因子貨號種屬表達(dá)宿主純度內(nèi)毒素Activin

A10429-HNAHHuman,

Mouse,

Rat,Cynomolgus,

RhesusHEK293Cells≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgGMP-10429-HNAHHuman,

Mouse,

Rat,Rhesus,

CanineHEK293Cells≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgBMP410609-HNAE2HumanE.

coli≥

95%

SDS<

1

EU/μgEGF10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgGMP-10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgNoggin10267-HNAHHumanHEK293Cells≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgbasic

FGF/FGF210014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgGMP-10014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgHGF10463-HNASHumanCHO

Stable

Cells≥

95%

SDS≥

95%

SEC-HPLC<

0.01

EU/μgHuman

EGF

Protein

(Cat#:

10605-HNAE)Human

IL3

Protein

(Cat#:

GMP-11858-HNAE)-201E-4

1E-3

0.01

0.1

1 10

100160140120100806040200Proliferation,%Human

EGF

Conc.

(ng/mL)Batch

1Batch

2Batch

3mAU400350300250200150100500kDa

M

11666.245.035.025.018.414.45

10

15

20

25

minHigh-purity:

≥

95

%

as

determinedbySDS-PAGE

&

SEC-HPLC.-200Proliferation,%1E-5

1E-4

1E-3

0.01

0.1 1

10

100

1000Human

IL3Conc.(ng/mL)1600

SinobiologicalBatch11400

SinobiologicalBatch21200

SinobiologicalBatch310008006004002000mAU

14012010080604020011666.245.035.025.018.414.4kDa

M5

10

15

20

25

minHigh-purity:

≥

95

%

as

determinedbySDS-PAGE

&

SEC-HPLC.1E-4

1E-3

0.01

0.1

1 10

100

1000Human

IL3Conc.(ng/mL)Activity-validated:

Cell

proliferation

assay

usingTF-1

human

erythroleukemic

cells120010008006004002000Proliferation,%1400

ED

=0.15-0.75

ng/mL50Human

vascular

organoids

derived

from

iPSCswere

cultured

using

FGF2,

VEGFA,

and

EGF.

Thevascular

organoids

are

indicated

by

redarrows.High

batch-to-batch

consistency:

Cellproliferation

assayusing

Balb/C

3T3

mouseembryonic

?broblasts.High

batch-to-batch

consistency:

Cellproliferation

assay

using

TF-1

humanerythroleukemic

cells.北京義翹神州科技股份有限公司08干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊細(xì)胞因子貨號種屬表達(dá)宿主純度內(nèi)毒素Flt3

Ligand/FLT3LG10315-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgGMP-10315-HNAE1-L-AFHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgGM-CSF/CSF210015-HNAHHumanHEK293Cells≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgGMP-10015-HNAHHumanHEK293Cells≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgIL-610395-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgGMP-10395-HNAEHumanE.

coli≥

95%

SDS<

5

EU/mgIL-2110584-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgGMP-10584-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgGMP-10584-HNAE1-L-AFHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

10

EU/mgT細(xì)胞參與造血干細(xì)胞分化的細(xì)胞因子示意圖造血干細(xì)胞（Hematopoieticstemcells,HSC）是一種具有自我更新能力和多向分化為各類血細(xì)胞特性的細(xì)胞，包括骨髓系和淋巴系細(xì)胞，在維持血液系統(tǒng)的建立和動態(tài)平衡中具有極其重要的作用。HSC存在于多種血液系統(tǒng)中，例如外周血、骨髓和臍帶血等。造血干細(xì)胞可以替代異常的造血組織和免疫組織，是治療血液惡性腫瘤和肝病等疾病的有力工具。HSC培養(yǎng)細(xì)胞因子推薦義翹神州提供大量HSC培養(yǎng)用細(xì)胞因子，其中包含多種GMP級細(xì)胞因子，全面支持HSC研究。造血干細(xì)胞培養(yǎng)GMP級細(xì)胞因子，現(xiàn)貨供應(yīng)無動物源細(xì)胞因子內(nèi)胚層巨核細(xì)胞B細(xì)胞單核細(xì)胞嗜中性粒細(xì)胞Flt3LSCFTPO

HSC自分化GM-CSFG-CSFIL-6M-CSFGM-CSFIL-7

SCFVCAM-1SCFEPOIL-3ICAM-1VCAM-1Flt3L

IL-7SCFTPOIL-3HSC09干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊產(chǎn)品驗證數(shù)據(jù)展示GMP級細(xì)胞因子，現(xiàn)貨供應(yīng)北京義翹神州科技股份有限公司GMP-grade

Human

IFN

gamma(Cat#:

GMP-11725-HNAE)GMP-grade

Human

GM-CSF/CSF2(Cat#:

GMP-10015-HNAH)GMP-grade

Human

IL-6(Cat#:

GMP-10395-HNAE)GMP-grade

Human

IL-21

(Cat#:

GMP-10584-HNAE)GMP-grade

Human

IL-4(Cat#:

GMP-11846-HNAE)GMP-grade

Human

IL-2(Cat#:

GMP-11848-HNAE)Five

tests

were

conducted

at

different

times

toverify

GMP-grade

human

IL-6

stability.Five

cycles

of

freeze-thaw

tests

wereconducted

to

verify

GMP-gradehuman

IL-6

stability.Six

tests

were

conducted

at

differenttimes

to

verify

GMP-grade

human

IL-4stability.0.300.350.400.500.45OD-Blank0.250.1

1

10

100Human

IFN

gamma

Conc.

(pg/mL)Measured

in

anti-viral

assays

usingWISH

cells

infected

with

vesicularstomatitis

virus

(VSV).ED50=8-80

pg/mL01000200030004000Proliferation,%1E-5

1E-4

1E-3

0.01

0.1

1 10

100Human

GM-CSF

Conc.

(ng/mL)Measured

in

a

cell

proliferation

assay

usingTF-1

human

erythroleukemic

cells.ED50=0.06-0.3

ng/mL10Proliferation,%Human

IL-2

Conc.

(ng/mL)Measured

in

a

cell

proliferationassay

using

CTLL2.600

ED50=1-8

ng/mL5004003002001000-1000.1

10.1

1 10

1003002001000-1001E-5

1E-4

1E-3

0.01600500400Proliferation,%Human

IL-6

Conc.

(ng/mL)Measured

in

a

cell

proliferation

assay

usingTF-1

human

erythroleukemic

cells.50ED

=0.1-0.8ng/mL1E-3

0.01

0.1

1

10

10016001400120010008006004002000-200Conc

of

Secretion

IFN-r.(pg/ml)Human

IL-21

Conc.

(ng/mL)Three

and

?ve

cycles

of

freeze-thaw

tests

wereconducted

to

verify

GMP-grade

human

IL-21

stability.freeze-thaw

0

timesfreeze-thaw

3timesfreeze-thaw

5

times1E-3

0.01

0.1

1

10

100Conc

of

Secretion

IFN-r.(pg/ml)Human

IL-21

Conc.

(ng/mL)Four

tests

were

conducted

at

different

timesto

verify

GMP-grade

human

IL-21

stability.2000

25℃

0

day1800 25℃

16

day1600

25℃

24

day1400

25℃

48

day1200100080060040020001E-5

1E-4

1E-3

0.01

0.1

1

10

1008007006005004003002001000Proliferation,%HumanIL-4

Conc.

(ng/mL)37℃

0

day37℃

7

day37℃

11

day37℃

15

day37℃

18

day37℃

35

day37℃

0

day37℃

7

days37℃

11

days37℃

15

days37℃

18

days10

100-1001E-5

1E-4

1E-3

0.01

0.1

16005004003002001000Proliferation,%Human

IL-6

Conc.

(ng/mL)1E-5

1E-4

1E-3

0.01

0.1

1 10

100

1000150100500200300250Proliferation,%Human

IL-6

Conc.

(ng/mL)Freeze-thaw

0

timeFreeze-thaw

5

times北京義翹神州科技股份有限公司10干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊細(xì)胞因子貨號種屬表達(dá)宿主純度內(nèi)毒素BDNF50240-M08HMouseHEK293Cells95%

SDS<

1

EU/μgBMP-210426-HNAE1Human,

Mouse,

Rat,Rhesus,

CanineE.

coli≥

95%

SDS<

10

EU/mgEGF10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgGMP-10605-HNAEHumanE.

coli≥

95%

SDS≥

95%

SEC-HPLC<

5

EU/mgbasic

FGF/FGF210014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgGMP-10014-HNAEHumanE.

coli≥

95%

SDS<

10

EU/mgSonic

Hedgehog/SHH10372-H08H1HumanHEK293Cells95%

SDS<

1

EU/μg參與神經(jīng)干細(xì)胞分化的細(xì)胞因子示意圖神經(jīng)干細(xì)胞（Neural

stemcell,NSCs）是存在于神經(jīng)系統(tǒng)中，能進(jìn)行自我更新，并具有分化為神經(jīng)元、星形膠質(zhì)細(xì)胞和少突膠質(zhì)細(xì)胞潛能的細(xì)胞群，能產(chǎn)生大量腦組織細(xì)胞。研究表明，NSC在特定條件下分化為相應(yīng)的功能細(xì)胞，從而替代缺失細(xì)胞，恢復(fù)原有的功能，在神經(jīng)發(fā)育和修復(fù)受損神經(jīng)組織中發(fā)揮重要作用。NSC培養(yǎng)細(xì)胞因子推薦神經(jīng)干細(xì)胞培養(yǎng)GMP級細(xì)胞因子，現(xiàn)貨供應(yīng)神經(jīng)干細(xì)胞神經(jīng)元脊髓運動神經(jīng)元多巴胺能神經(jīng)元谷氨酸能神經(jīng)元GABA神經(jīng)元海馬神經(jīng)元少突細(xì)胞星形膠質(zhì)細(xì)胞神經(jīng)元祖細(xì)胞神經(jīng)膠質(zhì)祖細(xì)胞EGF

FGF2PDGF-BB

VEGFbeta-NGFCNTF

FGF2PDGF-BBEGF

FGF2

CNTF

IGF-1PDGF-BBCNTF

EGFEGFbasic

FGF

FGF-10Sonic

Hedgehog/SHHFGF2PDGF-BBBDNF

CNTF

GDNF

IGF-1BDNF

FGF4

FGF8

SHHBMP2

BMP4

FGF8BDNF

GDNF

IGF-1NT-4

SHHBDNF

IGF-1北京義翹神州科技股份有限公司11干細(xì)胞培養(yǎng)細(xì)胞因子研究手冊產(chǎn)品驗證數(shù)據(jù)展示Human